SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-095393
Filing Date
2024-11-07
Accepted
2024-11-07 16:01:45
Documents
58
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0218928-10q_cadrenal.htm   iXBRL 10-Q 530588
2 CERTIFICATION ea021892801ex31-1_cadrenal.htm EX-31.1 10964
3 CERTIFICATION ea021892801ex31-2_cadrenal.htm EX-31.2 11402
4 CERTIFICATION ea021892801ex32-1_cadrenal.htm EX-32.1 4328
5 CERTIFICATION ea021892801ex32-2_cadrenal.htm EX-32.2 4546
  Complete submission text file 0001213900-24-095393.txt   4082176

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cvkd-20240930.xsd EX-101.SCH 37772
7 XBRL CALCULATION FILE cvkd-20240930_cal.xml EX-101.CAL 28392
8 XBRL DEFINITION FILE cvkd-20240930_def.xml EX-101.DEF 200281
9 XBRL LABEL FILE cvkd-20240930_lab.xml EX-101.LAB 367750
10 XBRL PRESENTATION FILE cvkd-20240930_pre.xml EX-101.PRE 210443
60 EXTRACTED XBRL INSTANCE DOCUMENT ea0218928-10q_cadrenal_htm.xml XML 417285
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

IRS No.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41596 | Film No.: 241435393
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)